PFO
AERI

Pathstone Family Office’s Aerie Pharmaceuticals AERI Stock Holding History

Pathstone Family Office’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-70
Closed -$1K – 1023
2020
Q1 		$1K Buy
+70
New +$1.33K ﹤0.01% 747

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pathstone Family Office's AERI Position: Q2 2020 in Review

Pathstone Family Office sold out of Aerie Pharmaceuticals (AERI) in Q2 2020, closing a stake of 70 shares — an estimated $1K sold.

Pathstone Family Office first reported a position in AERI in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 155 funds tracked by Wall St. Rank hold AERI as of Q2 2020.

  • Pathstone Family Office reported no remaining Aerie Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Pathstone Family Office sold 70 Aerie Pharmaceuticals shares in Q2 2020, an estimated $1K.
  • Pathstone Family Office first reported a position in Aerie Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Pathstone Family Office's Aerie Pharmaceuticals position peaked at $1K in Q1 2020.
  • 155 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.